Literature DB >> 21160960

Future perspectives on the treatment of hepatocellular carcinoma with cisplatin.

Toru Ishikawa1.   

Abstract

Hepatocellular carcinoma (HCC) is the commonest primary liver malignancy. Its incidence is increasing worldwide. Surgery, including transplantation resection, is currently the most effective treatment for HCC. However, recurrence rates are high and long-term survival is poor. Conventional cytotoxic chemotherapy has not provided clinical benefit or prolonged survival for patients with advanced HCC. Cisplatin (CDDP) is a key drug for the standard regimens of various cancers in the respiratory, digestive and genitourinary organs. Recently, several encouraging results have been shown in using CDDP in the treatment of advanced HCC patients. This review examines current knowledge regarding the chemotherapeutic potential of CDDP.

Entities:  

Keywords:  Cisplatin; Hepatic arterial infusion; Hepatocellular carcinoma

Year:  2009        PMID： 21160960      PMCID： PMC2998955          DOI： 10.4254/wjh.v1.i1.8

Source DB:  PubMed          Journal:  World J Hepatol


  56 in total

1.  Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion.

Authors:  K Kamada; T Nakanishi; M Kitamoto; H Aikata; Y Kawakami; K Ito; T Asahara; G Kajiyama
Journal:  J Vasc Interv Radiol       Date:  2001-07       Impact factor: 3.464

2.  Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan.

Authors:  Masatoshi Makuuchi; Norihiro Kokudo
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

3.  Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced hepatocellular carcinoma.

Authors:  Chi-Pin Lin; Hsien-Chung Yu; Jin-Shiung Cheng; Kwok-Hung Lai; Gin-Ho Lo; Ping-I Hsu; Chiun-Ku Lin; Hoi-Hung Chen; Ching-Chu Lo; Huei-Lung Liang; Hui-Hwa Tseng
Journal:  J Chin Med Assoc       Date:  2004-12       Impact factor: 2.743

4.  Hepatic artery chemoembolization for advanced stage HCC: experience of 650 patients.

Authors:  Brian I Carr
Journal:  Hepatogastroenterology       Date:  2002 Jan-Feb

5.  Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies.

Authors:  H Yodono; T Sasaki; K Tarusawa; H Midorikawa; Y Saito; S D Takekawa
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Superselective intra-arterial chemotherapy with mitomycin C in hepatic neoplasms.

Authors:  J Mäkelä; T Tikkakoski; A Leinonen; T Siniluoto; A Karttunen; M I Kairaluoma
Journal:  Eur J Surg Oncol       Date:  1993-08       Impact factor: 4.424

7.  A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma.

Authors:  P M Parikh; J Fuloria; G Babu; D C Doval; B S Awasthy; V R Pai; P S Prabhakaran; A B Benson
Journal:  Trop Gastroenterol       Date:  2005 Jul-Sep

8.  Long-term follow-up of hepatic arterial chemoembolization with cisplatin suspended in iodized oil for hepatocellular carcinoma.

Authors:  Seishi Maeda; Junji Shibata; Shigetoshi Fujiyama; Motohiko Tanaka; Shinji Noumaru; Kinmochi Sato; Kimio Tomita
Journal:  Hepatogastroenterology       Date:  2003 May-Jun

9.  Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma.

Authors:  Masafumi Ikeda; Takuji Okusaka; Hideki Ueno; Chigusa Morizane; Yasushi Kojima; Satoru Iwasa; Atsushi Hagihara
Journal:  Jpn J Clin Oncol       Date:  2008-08-20       Impact factor: 3.019

10.  Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma.

Authors:  Se Hoon Park; Yuna Lee; Sang Hoon Han; So Young Kwon; Oh Sang Kwon; Sun Suk Kim; Ju Hyun Kim; Yeon Ho Park; Jeong Nam Lee; Soo-Mee Bang; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee
Journal:  BMC Cancer       Date:  2006-01-05       Impact factor: 4.430
View more
  12 in total

Review 1.  Strategy for improving survival and reducing recurrence of HCV-related hepatocellular carcinoma.

Authors:  Toru Ishikawa
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

2.  Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma.

Authors:  Kenya Kamimura; Takeshi Suda; Yasushi Tamura; Masaaki Takamura; Takeshi Yokoo; Masato Igarashi; Hirokazu Kawai; Satoshi Yamagiwa; Minoru Nomoto; Yutaka Aoyagi
Journal:  BMC Gastroenterol       Date:  2012-09-20       Impact factor: 3.067

3.  Fermented wheat germ extract induced cell death and enhanced cytotoxicity of Cisplatin and 5-Fluorouracil on human hepatocellular carcinoma cells.

Authors:  Cheng-Jeng Tai; Wen-Ching Wang; Chien-Kai Wang; Chih-Hsiung Wu; Mei-Due Yang; Yu-Jia Chang; Jiun-Yu Jian; Chen-Jei Tai
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-22       Impact factor: 2.629

4.  RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo.

Authors:  Wei Wang; Jianwen Cheng; Jiang-Jiang Qin; Sukesh Voruganti; Subhasree Nag; Jia Fan; Qiang Gao; Ruiwen Zhang
Journal:  Oncotarget       Date:  2014-11-30

5.  Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial.

Authors:  Kenya Kamimura; Takeshi Suda; Takeshi Yokoo; Hiroteru Kamimura; Tsutomu Kanefuji; Atsunori Tsuchiya; Masaaki Takamura; Hirokazu Kawai; Nobuo Waguri; Satoshi Yamagiwa; Shuji Terai
Journal:  BMC Cancer       Date:  2017-05-10       Impact factor: 4.430

6.  The Antioxidant Carrichtera annua DC. Ethanolic Extract Counteracts Cisplatin Triggered Hepatic and Renal Toxicities.

Authors:  Enas E Eltamany; Sameh S Elhady; Mohamed S Nafie; Haidy A Ahmed; Dina M Abo-Elmatty; Safwat A Ahmed; Jihan M Badr; Asmaa R Abdel-Hamed
Journal:  Antioxidants (Basel)       Date:  2021-05-21

7.  Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma.

Authors:  Hiroki Nishikawa; Yukio Osaki; Eriko Iguchi; Haruhiko Takeda; Jun Nakajima; Fumihiro Matsuda; Azusa Sakamoto; Shinichiro Henmi; Keiichi Hatamaru; Sumio Saito; Akihiro Nasu; Ryuichi Kita; Toru Kimura
Journal:  Exp Ther Med       Date:  2012-06-15       Impact factor: 2.447

8.  Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan.

Authors:  Hiroki Nishikawa; Yukio Osaki; Ryuichi Kita; Toru Kimura
Journal:  Cancers (Basel)       Date:  2012-02-21       Impact factor: 6.639

9.  Protein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.

Authors:  Qunying Zhuang; Tengjian Zhou; Chengyong He; Shili Zhang; Yang Qiu; Bing Luo; Ran Zhao; Hengchuan Liu; Yuchun Lin; Zhongning Lin
Journal:  J Exp Clin Cancer Res       Date:  2016-04-14

10.  The Ethanolic Extract of Taiwanofungus camphoratus (Antrodia camphorata) Induces Cell Cycle Arrest and Enhances Cytotoxicity of Cisplatin and Doxorubicin on Human Hepatocellular Carcinoma Cells.

Authors:  Liang-Tzung Lin; Chen-Jei Tai; Ching-Hua Su; Fang-Mo Chang; Chen-Yen Choong; Chien-Kai Wang; Cheng-Jeng Tai
Journal:  Biomed Res Int       Date:  2015-10-18       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.